BMJ Open (Mar 2022)

Testing and treatment for latent tuberculosis infection in people living with HIV and substance dependence: a prospective cohort study

  • C Robert Horsburgh,
  • Richard Saitz,
  • Jeffrey H Samet,
  • Tessa Runels,
  • Elizabeth J Ragan,
  • Alicia S Ventura,
  • Michael R Winter,
  • Laura F White,
  • Karen R Jacobson

DOI
https://doi.org/10.1136/bmjopen-2021-058751
Journal volume & issue
Vol. 12, no. 3

Abstract

Read online

Objective To quantify the proportion of people living with HIV (PLWH) with other tuberculosis (TB) risk factors that completed the latent tuberculosis infection (LTBI) care cascade and describe factors associated with attrition. The care cascade was defined as follows: (1) receipt of an LTBI test and result, (2) initiation of LTBI treatment and (3) completion of LTBI treatment.Design Prospective cohort study.Setting Reactivation of LTBI remains a large source of active TB disease in the USA. PLWH and those who use substances are at greater risk and are harder to engage and retain in care.Participants Participants enrolled in a Boston cohort of PLWH from 2012 to 2014.Primary and secondary outcome measures Our primary outcome was the number and proportion of participants who completed each stage of the cascade and the factors associated with completing each stage. Our secondary outcomes were differences between participants tested with an interferon gamma release assay (IGRA) versus tuberculin skin test and differences between participants who tested positive versus negative for LTBI.Results Only 189 of 219 (86.3%) participants completed testing. Five of the 11 with LTBI initiated and three completed treatment. Participants tested with an IGRA were more likely to complete testing (OR 3.87, 95% CI 1.05 to 14.30) while among participants successfully tested, being foreign-born was associated with a positive test result (OR 3.95; 95% CI 1.13 to 13.77).Conclusions Although the majority completed LTBI testing, our findings warrant further investigation in a larger cohort to better understand factors that lead to suboptimal treatment initiation and completion in a low-burden country.